Abstract
Among 2752 patients with acute leukemia who had recurrent leukemia after autograft in remission and were reported to the EBMT, 94 underwent an allogeneic bone marrow transplant and 74 received a second autograft. Recipients of HLA-mismatched related or unrelated bone marrow had an increased transplant-related mortality (TRM, P = 0.017) and a decreased leukemia-free survival (LFS, P = 0.03), compared to recipients of HLA matched related or unrelated bone marrow. Outcome in recipients of HLA-compatible related or unrelated bone marrow was compared to those receiving a second autograft. TRM at 2 years was 51 ± 8% in recipients of matched allografts and 26 ± 6% following a 2nd autograft (P < 0.05). two-year lfs was 27 ± 7% and 35 ± 6% in the two groups, respectively (ns). multivariate analysis in these two groups showed that trm was increased in patients who were in 2nd or later remission at 1st autograft (P < 0.05) and allograft recipients (P < 0.05). relapse was more common in patients with all (P < 0.001), above 25 years of age (P < 0.02), autograft performed later than 1991 (P < 0.05), and in second autografts (P < 0.05). lfs was decreased in patients >25 years of age (P < 0.01), if the interval from first autograft to relapse was 8 months or less (P < 0.01) and if tbi was used at first autograft (P < 0.05).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Ringdén, O., Labopin, M., Frassoni, F. et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplant 24, 389–396 (1999). https://doi.org/10.1038/sj.bmt.1701918
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701918
Keywords
This article is cited by
-
Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
International Journal of Hematology (2017)
-
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Leukemia (2015)
-
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation
Bone Marrow Transplantation (2005)
-
Autologous stem cell transplantation in hematological malignancies
Springer Seminars in Immunopathology (2004)
-
Autologous stem cell transplantation for acute myeloid leukemia
Bone Marrow Transplantation (2003)